Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
European Respiratory Journal ; 58:2, 2021.
Article in English | Web of Science | ID: covidwho-1704115
2.
Zhonghua Jie He He Hu Xi Za Zhi ; 44(5): 435-442, 2021 May 12.
Article in Chinese | MEDLINE | ID: covidwho-1555709

ABSTRACT

Objective: To explore the clinical characteristics and risk factors of patients with Coronavirus Disease 2019 (COVID-19) when developing multiple organ dysfunction syndrome (MODS). Methods: Data from 458 inpatients of confirmed COVID-19 in Wuhan, Shanghai and Tongling from December 29, 2019 to March 24, 2020 were retrospectively collected. COVID-19 was confirmed by real-time RT-PCR of throat swab samples. Data of demographics, clinical presentation, laboratory tests, imaging findings, treatment and prognosis were obtained from medical record and compared between COVID-19 patients with and without MODS. Risk factors for the development of MODS were analyzed by univariate and multivariate logistic regression analysis. Results: Of the 458 COVID-19 patients (266 from Wuhan, 208 from Shanghai, and 24 from Tongling), 103 developed transient or persistent MODS in the course. More male patients were found in those with MODS (72.8% vs 54.6%, P=0.001). And MODS patients were of older age (72.8% vs 54.6%, P=0.001), more chronic comorbidities (68.0% vs 43.4%, P<0.001), and longer onset-to-admission interval (9.0 vs 7.0 d, P<0.001). In addition, patients with MODS had more expectoration (45.6% vs 29.9%, P=0.003) and shortness of breath (52.4% vs 19.4%, P<0.001), dysfunction of various systems, decreased cellular immunity and elevated IL-6 (9.6 vs 7.6 g/L, P=0.015) in laboratory tests, isolation of other pathogens (18.4% vs 5.6%, P<0.001), and infiltration of all five lobes (75.3% vs 57.6%, P=0.003). During hospitalization, patients with MODS needed a higher proportion of comprehensive treatment and reached a mortality rate of 66.0%. Independents risk factors for development of MODS in COVID-19 patients were: onset-to-admission interval>7 days (OR=2.17, 95%CI: 1.11-4.22, P=0.023), shortness of breath (OR=3.19, 95%CI: 1.60-6.37, P=0.001), lymphocyte count<1×109/L (OR=2.67, 95%CI: 1.31-5.46, P=0.007), blood urea nitrogen>7mol/L (OR=6.27, 95%CI: 2.80-14.08, P<0.001), procalcitonin>0.1 ng/mL (OR=2.48, 95%CI: 1.20-5.13, P=0.014), and C-reactive protein>10 mg/L (OR=3.92, 95%CI: 1.41-10.89, P=0.009). Conclusions: COVID-19 patients with MODS were of higher severity and mortality. Early identification of high-risk groups with MODS according to risk factors may be helpful for early treatment.


Subject(s)
COVID-19 , Multiple Organ Failure , Aged , China/epidemiology , Humans , Male , Multiple Organ Failure/epidemiology , Retrospective Studies , Risk Factors , SARS-CoV-2
3.
2020 Ieee Globecom Workshops ; 2020.
Article in English | Web of Science | ID: covidwho-1307625

ABSTRACT

Sneezes play a key role in transferring respiratory diseases such as COVID-19 between infectious and susceptible individuals where the timely monitoring and alerting for sneezes can be important in preventing the spread of such diseases. This paper presents Wi-Sneeze, a Wi-Fi based passive radar for sneeze sensing using Wi-Fi signals, as a promising solution to detect the potentially harmful exhaled volume-based sneeze droplets. Using the size distributions of the droplets exhaled by sneezes, an accurate volume RCS for the sneeze droplets is calculated, leading to the computation of the SNR which enable the range prediction for detecting the sneeze droplets. Experimental trials are conducted for real human sneezes and using the associated signal processing schemes, the Doppler frequency of the sneeze droplets can be prominently detected and localized in range. In addition, advanced signal processing techniques are used to improve the performance of the sneeze droplets detections. These promising results clearly validated the concept and feasibility of Wi-Sneeze in a practical environment.

4.
IEEE Globecom Workshops, GC Wkshps - Proc. ; 2020.
Article in English | Scopus | ID: covidwho-1151558
SELECTION OF CITATIONS
SEARCH DETAIL